We are absolutely delighted with the recent wave of media coverage celebrating a major milestone for Edinburgh Biosciences and our revolutionary cataract treatment, Revisyon.
Our story has featured across some of the most respected titles in Scottish and UK business and innovation media, including The Scotsman, Edinburgh Evening News, Daily Business, Scottish Business News, Silicon Scotland, Scottish Business Insider, Insider Media, and Business CNCT. This broad recognition is a testament to the significance of what we’re building: a future where cataract care is transformed from an operating theatre procedure to a simple, non-invasive treatment delivered on the high street.
At the heart of the coverage is the news that Edinburgh Biosciences has secured a £2.3 million loan investment. This funding will support the final stages of product development and the commercial launch of Revisyon, as we move ever closer to market readiness.
This follows a successful £2 million raise in 2023 from Innofield Biotechnology Ltd, a subsidiary of Boye Biotech, as part of a licensing and equity investment deal. With this support, we have successfully completed clinical trials on Revisyon, the world’s first non-surgical cataract treatment.
Revisyon represents a radical shift in cataract care, allowing treatment to be delivered by optometrists, reducing waiting times, and easing pressure on overstretched surgical services. We anticipate receiving the UKCA mark by the end of this year, paving the way for commercial rollout.
Our CEO, Graham Bell, recently shared early trial findings at the LSX World Congress in London on 29 April. The results are promising, showing clear improvement in visual acuity among trial participants. Full clinical trial data is due for publication this summer.
Revisyon is the brainchild of our founder, Prof Desmond Smith OBE, a pioneer in light-based medical technologies. His discovery that specific wavelengths of low-power LED light could reverse the aggregation of proteins responsible for cataracts has formed the foundation of this groundbreaking treatment.
We’re delighted to have our work recognised in the national media and excited about what’s ahead. Thank you to all our supporters and collaborators who are helping bring this innovation to life.
Stay tuned for more updates as we prepare to bring Revisyon to patients across the UK and beyond.
